TY - JOUR T1 - Burden is in the eye of the beholder: Sensitivity of yellow fever disease burden estimates to modeling assumptions JF - medRxiv DO - 10.1101/2021.01.06.21249311 SP - 2021.01.06.21249311 AU - T. Alex Perkins AU - John H. Huber AU - Quan Tran Minh AU - Rachel J. Oidtman AU - Magdalene K. Walters AU - Amir S. Siraj AU - Sean M. Moore Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/01/06/2021.01.06.21249311.abstract N2 - Geographically stratified estimates of disease burden play an important role in setting priorities for the management of different diseases and for targeting interventions against a single disease. Such estimates involve numerous assumptions, which uncertainty about is not always well accounted for. We developed a framework for estimating the burden of yellow fever in Africa and evaluated its sensitivity to assumptions about the interpretation of serological data and choice of regression model. We addressed the latter with an ensemble approach, and we found that the former resulted in a nearly twentyfold difference in burden estimates (range of central estimates: 8.4×104-1.5×106 deaths in 2021-2030). Even so, statistical uncertainty made even greater contributions to variance in burden estimates (87%). Combined with estimates that most infections go unreported (range of 95% credible intervals: 99.65-99.99%), our results suggest that yellow fever’s burden will remain highly uncertain without major improvements in surveillance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was carried out as part of the Vaccine Impact Modelling Consortium, which is funded by Gavi, the Vaccine Alliance, and the Bill & Melinda Gates Foundation (OPP1157270). The views expressed are those of the authors and not necessarily those of the Consortium or its funders. The final decision on the content of the publication was taken by the authors. JHH received support from a Graduate Research Fellowship from the National Science Foundation and a Richard and Peggy Notebaert Premier Fellowship from the University of Notre Dame. RJO received support from an Arthur J. Schmitt Leadership Fellowship in Science and Engineering and an Eck Institute for Global Health Fellowship from the University of Notre Dame. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request. ER -